NRAS and nasopharyngeal carcinoma: A study by Jiang et al. identified 24 hotspot mutations across 11 oncogenes (EGFR, CDK4, KIT, PDGFRA, KRAS, BRAF, MET, FGFR3, AKT1, PIK3CA, and NRAS) in NPC patients and found that KIT mutation was associated with poorer overall and relapse-free survival [17].